Promoting vascular repair in the retina: can stem/progenitor cells help?
Authors Trinh TLP, Li Calzi S, Shaw L, Yoder M, Grant M
Received 1 September 2015
Accepted for publication 4 December 2015
Published 26 May 2016 Volume 2016:8 Pages 113—122
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Margaret Wong-Riley
Thao Le Phuong Trinh,1 Sergio Li Calzi,1 Lynn C Shaw,1 Mervin C Yoder,2–4 Maria B Grant1
1Department of Ophthalmology, 2Department of Pediatrics, 3Herman B. Wells Center for Pediatric Research, 4Department of Biochemistry and Molecular Biology, Indiana University – Purdue University Indianapolis, Indianapolis, IN, USA
Abstract: Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a challenging illness in neonatology. Higher than physiological oxygen levels impede the development of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue the normal retinal vasculature, and each has significant safety concerns. The limitations of these approaches have led to new efforts to understand the pathological characteristics in each phase of ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and with the need for new treatments for ROP, this review discusses the possible future use of unique populations of proangiogenic cells for therapeutic revascularization of the preterm retina.
Keywords: retinopathy of prematurity, ROP therapy, endothelial progenitor cells, CD34+ cells, endothelial colony-forming cells, oxygen-induced retinopathy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]